Wednesday, November 25, 2009, 10:09am EST - Canadian Markets close in 5 hours and 51 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

Santarus Inc. (SNTS)

At 09:54 EST: 4.02 USD  Down 0.09 (2.19%)  
MORE ON SNTS
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
Santarus, Inc. (NGM:SNTS) Delayed quote dataEdit
Last Trade: 4.02 USD
Trade Time: 9:54AM EST
Change: Down 0.09 (2.19%)
Prev Close: 4.11
Open: 4.14
Bid: 4.02 x 100
Ask: 4.03 x 400
1y Target Est: 4.83
Day's Range: 4.01 - 4.12
52wk Range: 1.05 - 4.23
Volume: 34,908
Avg Vol (3m): 252,118
Market Cap: 233.46M
P/E (ttm): N/A
EPS (ttm): -0.05
Div & Yield: N/A (N/A%)
Santarus Inc. (SNTS)
1d  5d  3m  6m  1y  2y  5y  max 
 Add SNTS to Portfolio   Download Data

HEADLINES
Santarus to Present at Piper Jaffray 21st Annual Health Care Conference
Business Wire (Tue 4:01am)
Santarus' Zegrid Facing Back-to-Back FDA Approval Dates
at Seeking Alpha (Fri, Nov 20)
Santarus, Depomed Poised to Gain from Anticipated Sales of Glumetza
at Seeking Alpha (Mon, Nov 16)
[$$] Biotech Stock Mailbag: Cardium Therapeutics
at RealMoney by TheStreet.com (Fri, Nov 13)
SANTARUS INC Financials
EDGAR Online Financials (Tue, Nov 10)
SANTARUS INC Files SEC form 8-K, Other Events
EDGAR Online (Tue, Nov 10)
Santarus to Present at Lazard Capital Markets 6th Annual Healthcare Conference
Business Wire (Tue, Nov 10)
Santarus Reports Strong Quarter
Zacks.com (Sat, Nov 7)
New Star Analyst Rankings for Santarus, Inc.
StarMine (Thu, Nov 5)
Santarus Inc. Q3 2009 Earnings Call Transcript
at Seeking Alpha (Wed, Nov 4)
Santarus, Inc. Earnings Call scheduled for 5:00 pm ET today
CCBN (Wed, Nov 4)
Santarus Reports Third Quarter 2009 Financial Results
Business Wire (Wed, Nov 4)
SANTARUS INC Files SEC form 8-K, Results of Operations and Financial Condition
EDGAR Online (Wed, Nov 4)
More Headlines for SNTS...

ANALYST
EPS Est (next year) (Dec-09) : 0.26
EPS Est (in 2 years) (Dec-10) : 0.24
Avg Rec (current)*: 2.5
PEG Ratio: 1.44
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Santarus, Inc., a specialty pharmaceutical company, engages in acquiring, developing, and commercializing proprietary products that treat upper gastrointestinal diseases and disorders.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News Canadian Indices